Eurofins: almost 7% organic growth in Q1

(CercleFinance.com) - Eurofins Scientific has reported sales of E1.
65bn for Q1 2024, up 5% as reported, despite negative FX and calendar effects.

Excluding calendar effects, the bioanalytical services provider's organic revenues rose by 6.8% - above its target - for its core business (i.e. excluding revenues from Covid-19 tests and reagents).

Eurofins confirms its target for adjusted EBITDA of E1.525bn to E1.575bn, and sales of E7.075bn to E7.175bn, for 2024, as well as its 2027 targets of an adjusted EBITDA margin of 24% for sales of close to E10bn.


Copyright (c) 2024 CercleFinance.com. All rights reserved.